Nurturing the stem cell business: lessons from the recombinant drugs markets?
by Robert Junold, Rudiger Wink
International Journal of Biotechnology (IJBT), Vol. 8, No. 3/4, 2006

Abstract: The commercial use of embryonic or adult stem cells is still in its infancy. Most young firms concentrated on the generation and storage of stem cells, the development of tissues and related equipment. But the perspectives of therapeutic use of stem cells attract a lot of political and commercial attention to possible new strategic markets opening up new fields besides incumbent bio-pharmaceutical segments. The paper compares experiences of market emergence in recombinant drugs market as a typical bio-pharmaceutical market with the current situation in stem cell business. The results of this comparison lead to policy recommendations for nurturing stem cell business stressing particularly the role of examination knowledge and sales markets.

Online publication date: Wed, 15-Mar-2006

The full text of this article is only available to individual subscribers or to users at subscribing institutions.

 
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.

Pay per view:
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.

Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Biotechnology (IJBT):
Login with your Inderscience username and password:

Username:        Password:          Forgotten your password?

Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.

If you still need assistance, please email subs@inderscience.com